• This article examines whether Teladoc Health at US$7.34 is starting to look cheap or still carries more risk than reward, by breaking down what the current price might be implying about the stock.
• The share price has moved 4.1% over the last week and 8.1% over the last month, with a 4.1% return year to date. The return over 1 year sits at 7.0%, while the stock has fallen 70.5% over 3 years and 95.3% over 5 years.
• Recent news coverage has focused on Teladoc Health's role in telehealth and virtual care, as investors weigh ongoing adoption of digital health services and competition within the sector. Commentary has also highlighted that past volatility and sentiment around high growth healthcare stocks may still be influencing how the stock trades today.
• Teladoc Health currently holds a value score of 5/6. The sections that follow will compare different valuation methods, before returning to a broader way of thinking about what that score may mean for you as an investor.

Approach 1: Teladoc Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth today by projecting the company’s future cash flows and then discounting those cash flows back to a present value.

For Teladoc Health, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections. The latest twelve month Free Cash Flow is about $148.1 million. Analyst estimates and subsequent extrapolations suggest Free Cash Flow reaching about $178.8 million in 2030, with intermediate projections between 2026 and 2035 gradually stepping up over time. Simply Wall St uses analyst inputs where available and then extends those forecasts further out.

Bringing all of those projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of $13.70 per share. Compared with the recent share price of $7.34, this indicates that, on this model alone, Teladoc Health trades at about a 46.4% discount and appears undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Teladoc Health is undervalued by 46.4%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: Teladoc Health Price vs Sales

For companies where earnings are limited or volatile, the P/S ratio is often a useful way to think about valuation, because it focuses on what you pay for each dollar of revenue rather than profit.

In general, higher expected growth and lower perceived risk can justify a higher “normal” P/S multiple, while slower growth or higher uncertainty tend to align with a lower multiple. So context matters when you compare any single ratio.

Teladoc Health currently trades on a P/S ratio of 0.53x. This is well below the Healthcare Services industry average of 1.65x and also below the peer group average of 2.05x. Simply Wall St’s Fair Ratio for Teladoc Health is 1.77x, which reflects what investors might pay based on factors such as growth outlook, profit margins, industry, market cap and company specific risks.

The Fair Ratio can be more informative than a simple comparison with peers or the industry, because it is tailored to the company’s characteristics instead of assuming it should trade in line with a broad group.

With the current P/S at 0.53x compared with a Fair Ratio of 1.77x, the stock screens as undervalued on this measure.

Result: UNDERVALUED

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Upgrade Your Decision Making: Choose your Teladoc Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to turn your view of Teladoc Health into a story that links its business, your assumptions for future revenue, earnings and margins, and an implied fair value.

On Simply Wall St's Community page, Narratives let you set out that story clearly. They then automatically connect it to a financial forecast and a fair value estimate that you can compare with the current share price to help you decide whether the stock looks attractive, fairly priced or expensive based on your own expectations.

Narratives are updated as new information such as earnings or news flows through, so your fair value view moves with the data instead of staying frozen on old assumptions.

For Teladoc Health, one investor might build a cautious Narrative that lines up with a US$5.00 fair value while another might lean into a more optimistic Narrative closer to US$10.50. Seeing those side by side makes it easier for you to decide which story and set of assumptions feels more reasonable for your goals and risk tolerance.

For Teladoc Health, however, we'll make it really easy for you with previews of two leading Teladoc Health Narratives:

Fair value in this bullish narrative: US$10.50 per share

Implied discount to this fair value at US$7.34: about 30.1% undervalued

Revenue growth assumption used in this narrative: 2.2%

• Focuses on BetterHelp's shift toward insurance coverage and an integrated virtual care platform as potential drivers of higher margins over time.
• Assumes measured revenue growth, a move from losses to earnings by 2029, and a higher future P/E multiple than the current US Healthcare Services industry level.
• Highlights execution risks around competition, business model changes, and acquisitions that could challenge the more optimistic outcome.

Fair value in this bearish narrative: US$5.00 per share

Implied premium to this fair value at US$7.34: about 46.8% overvalued

Revenue growth assumption used in this narrative: 1.1% decline

• Emphasizes pressure on margins from higher compliance costs, intense competition, reimbursement uncertainty, and the mix shift at BetterHelp.
• Assumes slightly declining revenue over the next 3 years, with profitability only improving if margins eventually move toward the broader industry level.
• Flags that stronger international growth, new products, and cost control could challenge this cautious view if they translate into steadier cash flow and better earnings.

These two Narratives sit on opposite sides of the debate and are built from explicit revenue, margin, and valuation assumptions, so you can quickly see which set of expectations feels closer to your own view of Teladoc Health.

To see how these thesis previews compare with the wider set of community views and supporting data, you can review the full bull, bear, and consensus Narratives for Teladoc Health in one place, starting with the See what the community is saying about Teladoc Health.

Do you think there's more to the story for Teladoc Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.